Join the Glatiramer group to help and get support from people like you.
Glatiramer News
When Insurers Restrict MS Drug Coverage, Relapses Rise
TUESDAY, Aug. 5, 2025 — Multiple sclerosis (MS) patients might have a higher risk of relapse if their health insurance is stingy with prescriptions, a new study reports. Patients with insurance plans ...
Women Less Likely to Get Certain MS Meds Than Men
THURSDAY, July 31, 2025 — Women are less likely than men to receive multiple sclerosis (MS) meds that could help them manage the disease and delay disability, a new report finds. It could be that s...
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
THURSDAY, July 31, 2025 – Women with multiple sclerosis (MS) are less likely to receive disease-modifying therapies (DMTs) than men, according to a study published online July 30 in Neurology....
FDA Medwatch Alert: Drug Safety Communication: Copaxone, Glatopa (glatiramer acetate) - FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis
ISSUE: The FDA is warning about the risk of a rare but serious allergic reaction with the medicine glatiramer acetate (Copaxone, Glatopa), which is used to treat patients with multiple sclerosis...
FDA Medwatch Alert: Cross-Compatibility Issues with Autoinjector Devices Optional for Use with Glatiramer Acetate Injection
May 16, 2024 – FDA is alerting patients, caregivers, and health care professionals of labeling updates for glatiramer acetate injection products. Updated labeling includes a new warning that using...
FDA Medwatch Alert: FDA Alerts Patients, Caregivers, and Health Care Providers of Cross-Compatibility Issues with Autoinjector Devices That Are Optional for Use with Glatiramer Acetate Injection
August 18, 2022 – FDA is alerting patients, caregivers, and health care professionals that autoinjector devices that are optional for use with glatiramer acetate injection may not be compatible for...
FDA Approves Glatopa (glatiramer acetate) as the First Generic Competitor to Copaxone
Holzkirchen, Germany, April 16, 2015 - Sandoz, a Novartis company, today announced the US approval of Glatopa, the first generic version of Teva's Copaxone (glatiramer acetate injection) 20 mg/ml...
Teva Announces U.S. FDA Approval of Three-Times-a-Week Copaxone (glatiramer acetate injection) 40mg/mL
JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental new drug a...